Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype

• Published in: Cancers Vol. 12; no. 7; p. 1891
• Main Authors: Heibl, Sonja, Gisslinger, Bettina, Jäger, Eva, Barna, Agnes, Gurbisz, Michael, Stegemann, Maike, Bettelheim, Peter, Machherndl-Spandl, Sigrid, Pfeilstöcker, Michael, Nösslinger, Thomas, Uyanik, Gökhan, Hoermann, Gregor, Stauder, Reinhard, Thaler, Josef, Kusec, Rajko, Valent, Peter, Gisslinger, Heinz, Geissler, Klaus
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 14.07.2020; MDPI
• Subjects: Blood; Chronic myelomonocytic leukemia; Genotype & phenotype; Hematology; Hemoglobin; Janus kinase 2; Leukemia; Medical prognosis; Mutation; Myelofibrosis; Myelomonocytic leukemia; myeloproliferative neoplasm; NGS; Patients; Phenotypes; Polycythemia; Polycythemia vera; progenitor cells; prognosis; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12071891

Patients with a myeloproliferative neoplasm (MPN) sometimes show a chronic myelomonocytic leukemia (CMML)-like phenotype but, according to the 2016 WHO classification, a documented history of an MPN excludes the diagnosis of CMML. Forty-one patients with an MPN (35 polycythemia vera (PV), 5 primary myelofibrosis, 1 essential thrombocythemia) and a CMML-like phenotype (MPN/CMML) were comprehensively characterized regarding clinical, hematologic, biologic and molecular features. The white blood cell counts in MPN/CMML patients were not different from CMML patients and PV patients. The hemoglobin values and platelet counts of these patients were higher than in CMML but lower than in PV, respectively. MPN/CMML patients showed myelomonocytic skewing, a typical in vitro feature of CMML but not of PV. The mutational landscape of MPN/CMML was not different from JAK2-mutated CMML. In two MPN/CMML patients, development of a CMML-like phenotype was associated with a decrease in the JAK2 V617F allelic burden. Finally, the prognosis of MPN/CMML (median overall survival (OS) 27 months) was more similar to CMML (JAK2-mutated, 28 months; JAK2-nonmutated 29 months) than to PV (186 months). In conclusion, we show that patients with MPN and a CMML-like phenotype share more characteristics with CMML than with PV, which may be relevant for their classification and clinical management.